The case for adjuvant cyclo phosphamide methotrexate 5 fluoro uracil chemo therapy in breast cancer has it been made?

Levitt, S.H.; Potish, R.A.

Cancer Clinical Trials 4(4): 363-370

1981


ISSN/ISBN: 0190-1206
Accession: 006611373

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
The utility of adjuvant CMF [cyclophosphamide, methotrexate, 5-fluorouracil] in the treatment of breast cancer was reanalyzed. The actual percentage of patients who benefit from adjuvant CMF was relatively small. The widespread use of adjuvant CMF must be further examined.